Gravholt Claus Højbjerg, Poulsen Henrik Enghusen, Ott Peter, Christiansen Jens Sandahl, Vilstrup Hendrik
Medical Department M (Endocrinology and Diabetes), Aarhus Sygehus, Nørrebrogade, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.
Eur J Endocrinol. 2007 Jun;156(6):679-86. doi: 10.1530/EJE-07-0070.
Studies have documented elevated levels of liver enzymes in many females with Turner syndrome (TS). Histology has shown a range of changes. Treatment with female hormone replacement therapy (HRT) reduces liver enzymes.
To study quantitative liver functions in TS in detail with and without HRT.
Randomized crossover study with active treatment (HRT in TS and P-pill in controls) or no treatment.
Women with TS (n = 8, age 29.7 +/- 5.6 (mean +/- s.d.) years), verified by karyotype, and age-matched controls (C; n = 8, age 27.3 +/- 4.9 years).
We determined liver enzymes in blood, used the galactose elimination capacity to assess hepatocyte cytosol activity, plasma clearance of indocyanine green to assess excretory function, antipyrine clearance to estimate microsomal activity, and the functional hepatic nitrogen clearance (FHNC) to assess mitochondrial-cytosolic metabolic capacity for conversion of amino-nitrogen.
Liver enzymes were elevated in untreated TS and reduced by HRT. The hepatic capacities for conversion of galactose, indocyanine green, and antipyrine were normal and did not change by HRT. The FHNC was marginally reduced (untreated TS vs C: 19.4 +/- 5.4 vs 25.2 +/- 7.3 L/h, P = 0.1). FHNC changed slightly with HRT in TS (19.4 +/- 5.4 vs 24.4 +/- 10.2 L/h, P = 0.2).
The elevations of liver enzymes in untreated TS are readily suppressed by HRT. Quantitative liver functions in TS are comparable to controls and are not affected by HRT.
研究记录了许多特纳综合征(TS)女性的肝酶水平升高。组织学显示了一系列变化。女性激素替代疗法(HRT)可降低肝酶水平。
详细研究接受和未接受HRT的TS患者的肝脏定量功能。
采用活性治疗(TS患者接受HRT,对照组接受安慰剂)或不治疗的随机交叉研究。
经核型分析确诊的TS女性(n = 8,年龄29.7±5.6(均值±标准差)岁),以及年龄匹配的对照组(C;n = 8,年龄27.3±4.9岁)。
我们测定了血液中的肝酶,利用半乳糖清除能力评估肝细胞胞浆活性,吲哚菁绿的血浆清除率评估排泄功能,安替比林清除率估计微粒体活性,以及功能性肝氮清除率(FHNC)评估线粒体-胞浆将氨基氮转化的代谢能力。
未经治疗的TS患者肝酶升高,HRT可使其降低。半乳糖、吲哚菁绿和安替比林的肝脏转化能力正常,且不受HRT影响。FHNC略有降低(未治疗的TS患者与对照组:19.4±5.4 vs 25.2±7.3 L/h,P = 0.1)。TS患者接受HRT后FHNC略有变化(19.4±5.4 vs 24.4±10.2 L/h,P = 0.2)。
未治疗的TS患者肝酶升高可通过HRT轻易抑制。TS患者的肝脏定量功能与对照组相当,且不受HRT影响。